Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study

To assess the safety and efficacy of different doses of RTH258 applied as single intravitreal administration compared with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (AMD). Six-month, phase 1/2, prospective, multicenter, double-masked, randomized, ascending sing...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Ophthalmology (Rochester, Minn.) Ročník 123; číslo 5; s. 1080
Hlavní autoři:	Holz, Frank G, Dugel, Pravin U, Weissgerber, Georges, Hamilton, Robin, Silva, Rufino, Bandello, Francesco, Larsen, Michael, Weichselberger, Andreas, Wenzel, Andreas, Schmidt, Anne, Escher, Dominik, Sararols, Laura, Souied, Eric
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.05.2016
Témata:	Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Double-Blind Method Female Fluorescein Angiography Humans Immunoglobulin Fragments - immunology Intravitreal Injections Male Prospective Studies Ranibizumab - administration & dosage Single-Chain Antibodies - immunology Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity Wet Macular Degeneration - diagnosis Wet Macular Degeneration - physiopathology Wet Macular Degeneration - therapy
ISSN:	1549-4713, 1549-4713
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!